Lilly’s Alzheimer’s drug donanemab slows cognitive decline by 35% in PhIII, setting up showdown with Eisai’s Leqembi
At long last, Eli Lilly has found success in its decades-long effort to develop a treatment for Alzheimer’s disease.
The company announced Wednesday morning that its experimental drug, donanemab, slowed a key measure of cognitive and functional decline by 35% over 18 months in a subset of patients with early Alzheimer’s disease.
The highly anticipated Phase III study, known as TRAILBLAZER-ALZ 2, also succeeded on all its primary and secondary endpoints, bucking a long series of failed Alzheimer’s studies from Lilly and others. The company said it plans to submit the drug to the FDA “as quickly as possible” this quarter.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.